Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03669263
Recruitment Status : Completed
First Posted : September 13, 2018
Last Update Posted : September 13, 2018
Sponsor:
Collaborator:
TTY Biopharm
Information provided by (Responsible Party):
Chang Gung Memorial Hospital

Brief Summary:

Primary Objective:

To determine the feasible dose range of Painkyl® required for Taiwanese population.

Secondary Objectives:

To evaluate the efficacy of Painkyl® by calculating squared mean of pain intensity difference at 30 minutes after taking Painkyl® (SPID30, an 11-point scale).

To evaluate subjects' satisfaction by conducting global evaluation of medication performance (a 5-point categorical scale).

To identify percentage of episodes requiring rescue medication during maintenance treatment period.

To evaluate the safety data of Painkyl® for breakthrough pain.


Condition or disease Intervention/treatment Phase
Breakthrough Cancer Pain Drug: Fentanyl buccal soluble film (FBSF) Not Applicable

Detailed Description:

The primary endpoint was the feasible range of FBSF required for Taiwanese population. The secondary endpoints were the difference in pain intensity at 30 minutes (PID30) after FBSF administration, subjects' satisfaction, and the percentage of episodes requiring rescue medications.

Pain intensity was determined using an 11-point numeric scale from 0="no pain" to 10="worst pain." Patients were assessed with baseline pain as well as pain intensity at 30 minutes after dosing. The PID30 was obtained by baseline pain score minus score rated 30 minutes after dosing.

Patient's satisfaction was assessed using a 5-point (poor, fair, good, very good, and excellent) categorical scale at 30 minutes after taking FBSF with the following question: "What was your overall satisfaction with the medication?" At each episode of BTP, subjects recorded whether a rescue medication was taken after administration of FBSF.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fentanyl Buccal Soluble Films Feasible Dose Range Study for Breakthrough Pain in Taiwanese Cancer Patients
Actual Study Start Date : November 25, 2014
Actual Primary Completion Date : June 23, 2016
Actual Study Completion Date : July 1, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fentanyl buccal soluble film (FBSF)
Single arm
Drug: Fentanyl buccal soluble film (FBSF)

After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.

During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed.

Other Name: Painkyl, fentanyl buccal soluble film (FBSF)




Primary Outcome Measures :
  1. Optimal dose calculation of Painkyl® [ Time Frame: Within 2 weeks ]
    Time to "optimal" dose of an open-label study medication in the titration phase. During the dose titration period, subjects were administered with FBSF (Painkyl®) in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved.


Secondary Outcome Measures :
  1. Efficacy Phase : Pain intensity difference at 30 minutes (PID30) after treatment [ Time Frame: During the efficacy phase, at each episode of breakthrough pain, 30 minutes after taking dose of study drug, at 0 and 10 minutes after taking dose of study drug ]
    During the efficacy phase participants assessed their pain intensity at each breakthrough pain (BTP) episode at 0 and 30 minutes after taking dose using the 11-point Numerical Rating Scale (NRS) on a scale from 0 to 10, where 0 represents the absence of pain and 10 is "worst possible pain". PID30 is calculated as the difference in pain intensity from time 0 to 30 minutes. A positive value is a decrease (improvement) of the pain; a ≥ 3-point difference is considered as clinically important.

  2. Efficacy Phase : Subjects' satisfaction score at 30 minutes after treatment [ Time Frame: During the efficacy phase, at each episode of breakthrough pain, 30 minutes after taking dose of study drug ]
    Participants assessed their subjects' satisfaction of treatment efficacy for treated BTP episodes at 30 minutes after taking dose of study drug. The validated, categorical 5-point Verbal Rating Scale (VRS) was used for this assessment and scored as follows: poor; fair; good; very good; excellent.

  3. The percentage of episodes requiring rescue medications. [ Time Frame: Within 2 weeks ]
    • Percentage of episodes requiring rescue medications: subjects will record whether rescue medication was taken after study medication administration for each episode of BTP, by answering "yes" or "no."

  4. Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability] [ Time Frame: From the date of study entry until 30 days after the last dose of study treatment ]
    Assessed by the NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0 and within some subgroups of patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • a. a stable current regimen of oral opioids equivalent to 60-1000 mg/day of oral morphine or 20-120 mg/day of iv morphine or 25-300 mcg/hr of transdermal fentanyl for one week or longer;
  • b. regularly experienced 1 to 3 breakthrough pain episodes per day that required additional opioids from pain control;
  • c. at least partial relief of breakthrough pain by use of opioid therapy;
  • d. 20 years of age or older;
  • e. ability to understand and willingness to sign a written informed consent document;
  • f. able to self-administer the study medication correctly or has the availability of a responsible adult caregiver available to administer the study medication correctly;
  • g. willing and able to complete patient diary with each pain episode

Exclusion Criteria:

  • a. rapidly escalating pain (e.g., regularly more than 3 breakthrough pain episodes per day) that are hard to be controlled by analgesics;
  • b. history of hypersensitivity or intolerance to fentanyl;
  • c. cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression;
  • d. psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary;
  • e. moderate (Grade 3) to severe (Grade 4) mucositis (subjects with less than moderate mucositis are permitted and must be instructed to not apply the Painkyl® film at a site of inflammation);
  • f. abnormal oral mucosa which will impede drug absorption;
  • g. currently under other treatments that may alter effect of pain control based on investigator's judgment;
  • h. recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse;
  • i. use of an investigational drug within 4 weeks preceding this study;
  • j. pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03669263


Locations
Layout table for location information
Taiwan
Chang Gung Memorial Hospital
Keelung, Taiwan
Sponsors and Collaborators
Chang Gung Memorial Hospital
TTY Biopharm
Investigators
Layout table for investigator information
Study Chair: Cheng-Hsu Wang Chang Gung Memorial Hospital, Linkou, Taiwan
Publications:
Layout table for additonal information
Responsible Party: Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier: NCT03669263    
Other Study ID Numbers: PK1302
First Posted: September 13, 2018    Key Record Dates
Last Update Posted: September 13, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Chang Gung Memorial Hospital:
Painkyl®
fentanyl buccal soluble film
dose titration
Additional relevant MeSH terms:
Layout table for MeSH terms
Cancer Pain
Pain
Neurologic Manifestations
Fentanyl
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics